Total Payments
$381,191
2024 Payments
$187,396
Companies
20
Transactions
194
Payment Breakdown by Category
Research$347,838 (91.3%)
Travel$18,368 (4.8%)
Food & Beverage$7,423 (1.9%)
Other$5,410 (1.4%)
Consulting$2,153 (0.6%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $347,838 | 53 | 91.3% |
| Travel and Lodging | $18,368 | 55 | 4.8% |
| Food and Beverage | $7,423 | 80 | 1.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,410 | 4 | 1.4% |
| Consulting Fee | $2,153 | 2 | 0.6% |
Payments by Type
Research
$347,838
53 transactions
General
$33,353
141 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $315,332 | 25 | $0 (2024) |
| Avid Radiopharmaceuticals, Inc. | $19,670 | 1 | $0 (2021) |
| PFIZER INC. | $15,895 | 16 | $0 (2022) |
| Eisai Inc. | $5,388 | 52 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $3,393 | 20 | $0 (2019) |
| Takeda Pharmaceuticals U.S.A., Inc. | $2,654 | 3 | $0 (2018) |
| Novartis Pharma AG | $2,202 | 6 | $0 (2018) |
| Shionogi Inc | $1,941 | 3 | $0 (2023) |
| GlaxoSmithKline, LLC. | $1,928 | 9 | $0 (2020) |
| Genentech, Inc. | $1,914 | 6 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $187,396 | 15 | Eli Lilly and Company ($186,393) |
| 2023 | $22,939 | 15 | Eli Lilly and Company ($19,859) |
| 2022 | $37,659 | 29 | Eli Lilly and Company ($31,833) |
| 2021 | $36,861 | 4 | Avid Radiopharmaceuticals, Inc. ($19,670) |
| 2020 | $11,655 | 14 | Eli Lilly and Company ($8,294) |
| 2019 | $23,536 | 29 | Eli Lilly and Company ($15,440) |
| 2018 | $49,459 | 57 | Eli Lilly and Company ($36,563) |
| 2017 | $11,685 | 31 | Eli Lilly and Company ($2,958) |
All Payment Transactions
194 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $131,209.47 | Research |
| Study: A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $22,656.00 | Research |
| Study: A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | ||||||
| 09/24/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $6,271.00 | Research |
| Study: ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | ||||||
| 09/23/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $26,257.00 | Research |
| Study: A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | ||||||
| 09/11/2024 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $210.67 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $116.52 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $51.98 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $49.28 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $43.69 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $24.30 | General |
| 09/11/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $22.95 | General |
| 09/10/2024 | Eisai Inc. | — | Travel and Lodging | Cash or cash equivalent | $210.67 | General |
| 09/10/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $118.01 | General |
| 08/16/2024 | Lilly USA, LLC | AMYVID (Drug), KISUNLA | Food and Beverage | In-kind items and services | $33.81 | General |
| Category: Neuroscience | ||||||
| 07/31/2024 | Eisai Inc. | — | Food and Beverage | Cash or cash equivalent | $120.53 | General |
| 09/27/2023 | Shionogi Inc | — | Travel and Lodging | In-kind items and services | $1,473.36 | General |
| 09/27/2023 | Shionogi Inc | — | Travel and Lodging | In-kind items and services | $291.31 | General |
| 09/27/2023 | Shionogi Inc | — | Food and Beverage | In-kind items and services | $176.45 | General |
| 07/16/2023 | Eisai Inc. | Leqembi (Drug) | Food and Beverage | Cash or cash equivalent | $62.68 | General |
| Category: Neurology | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $428.92 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $56.32 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $46.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $46.61 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/15/2023 | Merck Sharp & Dohme LLC | — | Food and Beverage | In-kind items and services | $32.63 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/14/2023 | Merck Sharp & Dohme LLC | — | Travel and Lodging | In-kind items and services | $254.90 | General |
| Category: CARDIOVASCULAR | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) | Eli Lilly and Company | $131,209 | 1 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $57,240 | 2 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $53,204 | 4 |
| A MASTER PROTOCOL TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR OVERWEIGHT: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (TRIUMPH-1) | Eli Lilly and Company | $22,656 | 1 |
| H7I-AV-S029 | Avid Radiopharmaceuticals, Inc. | $19,670 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $19,094 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $15,681 | 2 |
| TANEZUMAB CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $8,280 | 4 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $6,271 | 1 |
| MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3303560 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMERS DISEASE OR MILD TO MODERATE ALZHEIMERS DISEASE | Eli Lilly and Company | $3,633 | 2 |
| Study to Qualify a Biomarker to Identify Subjects at Risk for MCI due to AD and to Evaluate Efficacy and Safety of Pioglitazone in Delaying Onset of MCI due to AD | Takeda Pharmaceuticals U.S.A., Inc. | $2,525 | 2 |
| A STUDY OF TIRZEPATIDE (LY3298176) ONCE A WEEK VERSUS INSULIN GLARGINE ONCE A DAY IN PARTICIPANTS WITH TYPE 2 DIABETES AND INCREASED CARDIOVASCULAR RISK | Eli Lilly and Company | $1,820 | 1 |
| Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease | Biogen, Inc. | $1,655 | 10 |
| A MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONT | GlaxoSmithKline, LLC. | $1,481 | 8 |
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Fasinumab in Patients With Moderate-to-Severe Chronic Low Back Pain and Osteoarthritis of the Hip or Knee | Regeneron Pharmaceuticals, Inc. | $1,355 | 7 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $465.00 | 1 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $451.35 | 2 |
| DONANEMAB FOLLOW-ON STUDY: SAFETY, TOLERABILITY, AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS | Eli Lilly and Company | $400.00 | 1 |
| DONANEMAB FOLLOW-ON STUDY: SAFETY TOLERABILITY AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS | Eli Lilly and Company | $300.00 | 1 |
About Dr. Alexander White, MD
Dr. Alexander White, MD is a Family Medicine healthcare provider based in Daytona Beach, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/18/2006. The National Provider Identifier (NPI) number assigned to this provider is 1285687459.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Alexander White, MD has received a total of $381,191 in payments from pharmaceutical and medical device companies, with $187,396 received in 2024. These payments were reported across 194 transactions from 20 companies. The most common payment nature is "" ($347,838).
Ad
Practice Information
- Specialty Family Medicine
- Location Daytona Beach, FL
- Active Since 05/18/2006
- Last Updated 04/05/2010
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1285687459
Products in Payments
- Non-Covered Product (Drug) $3,260
- Actos (Drug) $2,525
- LCZ696B (Drug) $2,202
- ENTRESTO (Drug) $1,896
- Tresiba (Drug) $1,659
- NUCALA (Biological) $1,481
- CNP520 (Drug) $676.33
- None (Drug) $268.54
- Lucentis (Biological) $222.77
- Fycompa (Drug) $159.82
- Leqembi (Drug) $62.68
- AMYVID (Drug) $33.81
- API015 (Drug) $25.45
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Daytona Beach
Dr. Brittany Newton, Md, MD
Family Medicine — Payments: $78,352
Family Medicine $78,352
Mr. Luther St. James, M.d, M.D
Family Medicine — Payments: $41,614
Family Medicine $41,614
Dr. Hugh Coleman, Do, DO
Family Medicine — Payments: $34,818
Family Medicine $34,818
Mrs. Carol Tanner-St. James, M.d, M.D
Family Medicine — Payments: $20,095
Family Medicine $20,095
Dr. David Billmeier, Md, MD
Family Medicine — Payments: $14,803
Family Medicine $14,803
Rachel Eyma, Md, MD
Family Medicine — Payments: $4,679
Family Medicine $4,679